All In Biotech

Drug Trial Radar · NCT04456387

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in Adolescent and Adult Patients With Hemophilia A.

Last checked: Nov 19, 2026Latest source record: Dec 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

Oct 15, 2020

Primary completion

Sep 30, 2021

Study completion Sep 30, 2021

Sponsor

Lead sponsor
Zhengzhou Gensciences IncIndustry
Sponsor type
Industry
First posted
Jul 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 12 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are to evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in the Prevention and Treatment of Bleeding in patients with hemophilia A. The secondary objectives are to evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in the prevention and treatment of bleeding episodes, to investigate the quality of life in patients who used the FRSW107.

Conditions

  • Hemophilia A

Interventions

  • Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionDrug

    Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.

  • Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionDrug

    Participants received prophylaxis treatment at 50 IU/kg every three days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A - score of bleeding symptoms and Vital signs.Time frame: For the duration of study participation, 6 months.
  2. Part B- Annualized Bleeding Rates(ABR).Time frame: For the duration of study participation, 6 months.
  3. Part B-Number of target joints.Time frame: For the duration of study participation, 6 months.

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Capital Medical University affiliated Beijing Children's Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Three Gorges Central Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangzhou, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Henan provincial People's Hospital

    Zhengzhou, He'nan, China

  • Henan Cancer Hospital

    Zhengzhou, He'nan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Affiliated Hospital of Xuzhou Medical College

    Xuzhou, Jiangsu, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • Jinan central hospital

    Ji'nan, Shandong, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.